Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer

P. O. Witteveen*, M. A C Van Groenestijn, G. H. Blijham, A. J P Schrijvers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

Background: In 1992 a home care technology project was started in which infusion therapy in the home setting was made available for patients with end-stage cancer. Beside aspects of feasibility and quality of life the resource utilization and costs of this transition was studied. Patients and methods: We conducted a cost evaluation study, to determine the actual cost of managing patients with end-stage cancer who require parenteral administration of fluid or analgesics in the home setting. A total of 128 patients were prospectively followed, with a detailed analysis of some aspects in a sample of 24 patients. Results: The cost for each patient was found to be between $250.00 and $300.00 per day, half of which are for hospital charges, even with this active home care technology program. One- third of the costs can be attributed to primary health care activities, in particular those of the district nurses. A hypothetical control group (n = 25) was constructed based on current practice and chart review. Patients in this group would have cost around $750.00 per day. With a median treatment period of 16 days this means a saving of $8000.00 per patient. Conclusion: Our data suggest that significant savings can be obtained by implementing programs transferring palliative care technology to the home setting.

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalAnnals of Oncology
Volume10
Issue number2
DOIs
Publication statusPublished - 15 Mar 1999

Keywords

  • Cost
  • End-stage cancer
  • Home care technology
  • Palliative care
  • Parenteral fluids and analgesics

Fingerprint

Dive into the research topics of 'Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer'. Together they form a unique fingerprint.

Cite this